Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Chubb
Farmers Insurance
Colorcon
McKesson
Julphar
Fuji
Fish and Richardson
Argus Health

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,133,890

« Back to Dashboard

Which drugs does patent 8,133,890 protect, and when does it expire?


Patent 8,133,890 protects COMBIGAN and is included in one NDA. There has been one Paragraph IV challenge on Combigan.

This patent has twenty-three patent family members in nineteen countries.

Summary for Patent: 8,133,890

Title:Combination of brimonidine and timolol for topical ophthalmic use
Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/946,828
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
COMBIGAN
brimonidine tartrate; timolol maleate
SOLUTION/DROPS;OPHTHALMIC021398-001Oct 30, 2007RXYesYes► Subscribe► Subscribe REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,133,890

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,030,149Combination of brimonidine timolol for topical ophthalmic use► Subscribe
9,474,751Combination of brimonidine and timolol for topical ophthalmic use► Subscribe
8,354,409Combination of brimonidine and timolol for topical ophthalmic use► Subscribe
7,323,463Combination of brimonidine and timolol for topical ophthalmic use► Subscribe
8,748,425Combination of brimonidine and timolol for topical ophthalmic use► Subscribe
7,320,976Combination of brimonidine and timolol for topical ophthalmic use► Subscribe
7,642,258Combination of brimonidine and timolol for topical ophthalmic use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,133,890

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1496912► Subscribe
China100558364► Subscribe
China101664414► Subscribe
European Patent Office2241319► Subscribe
Cyprus1114048► Subscribe
Denmark1496912► Subscribe
EcuadorSP034742► Subscribe
Spain2399045► Subscribe
Hong Kong1067549► Subscribe
Japan2005523316► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
Covington
Daiichi Sankyo
Deloitte
Mallinckrodt
Johnson and Johnson
Novartis
Cerilliant
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot